Dayvigo (Lemborexant) Regulatory Status: US, EU, Canada, and UK

What Is Lemborexant and How Does It Work

Lemborexant blocks the wake-promoting signals in your brain. Specifically, it is a dual orexin receptor antagonist (DORA) that competitively inhibits both orexin receptor subtypes, OX1R and OX2R, which are responsible for keeping you alert during waking hours.

The orexin system in plain terms

Orexins (also called hypocretins) are neuropeptides produced in the hypothalamus. Their primary job is to stabilize wakefulness and prevent the brain from slipping into sleep at the wrong time. When you have insomnia, that system can be overactive, particularly at night, making it hard to fall or stay asleep.

Lemborexant does not sedate you in the way a benzodiazepine does. Instead of amplifying inhibitory signals globally, it simply lifts the foot off the wakefulness accelerator. That distinction matters for next-morning function, a point the SUNRISE-1 trial (JAMA Network Open, 2019) specifically measured as a co-primary endpoint alongside sleep latency.

Where lemborexant sits in the DORA class

Suvorexant (Belsomra) was the first FDA-approved DORA in 2014. Lemborexant came second, with higher receptor binding affinity and a shorter half-life of roughly 17 to 19 hours compared with suvorexant's 12-hour half-life at the 20 mg dose. A longer half-life can mean more residual sedation in the morning, so this difference has practical consequences for women who drive early, care for children overnight, or who have slower drug metabolism due to hormonal status or liver enzyme activity.

Regulatory Status by Country

Lemborexant's approval history is uneven across regions. That gap is clinically significant if you are traveling, relocating, or receiving care across borders.

United States: FDA-approved December 2019

The FDA approved lemborexant on December 20, 2019, for the treatment of adults with insomnia characterized by difficulties with sleep onset, sleep maintenance, or both. It is classified as a Schedule IV controlled substance under the Controlled Substances Act, the same schedule as other sleep aids including zolpidem and suvorexant.

Available doses are 5 mg and 10 mg. The FDA-recommended starting dose is 5 mg at bedtime, with uptitration to 10 mg if 5 mg is tolerated but not sufficiently effective. The 10 mg dose is the maximum approved dose.

Canada: Health Canada approved 2021

Health Canada authorized lemborexant in 2021 under the brand name Dayvigo for the same adult insomnia indication. Dosing mirrors the US label: 5 mg starting dose with the option to increase to 10 mg. It is a Schedule IV targeted substance in Canada, requiring a prescription.

Japan: PMDA approved December 2019

Japan's Pharmaceuticals and Medical Devices Agency (PMDA) approved lemborexant simultaneously with the FDA in December 2019. Because Eisai is a Japanese pharmaceutical company, the simultaneous US-Japan filing was part of an integrated development program.

European Union: Not approved

The European Medicines Agency (EMA) has not granted marketing authorization for lemborexant as of early 2025. Eisai did not complete a standard centralized procedure for EU approval following the US launch. This means Dayvigo is not legally available in any EU member state through normal pharmacy channels. Women in Europe with insomnia needing a DORA have access only to suvorexant, which received EMA approval for insomnia in adults in 2021 under the brand name Belsomra.

United Kingdom: Not approved

Following Brexit, the UK's Medicines and Healthcare products Regulatory Agency (MHRA) operates independently of the EMA. Lemborexant does not hold an MHRA marketing authorization as of 2025. Again, suvorexant is the available DORA option in the UK.

Why Regulatory Status Matters for Women Specifically

A drug being approved or not approved in your region directly affects whether you can get it prescribed, insured, or legally imported. For women with insomnia driven by hormonal transitions, the choice of sleep agent is not interchangeable, because sex differences in drug clearance are real and well-documented.

Women clear zolpidem more slowly than men, which led the FDA to specifically lower the recommended zolpidem dose for women in 2013 to 5 mg from the previously standard 10 mg. The same caution should be applied when thinking about any sedative-hypnotic, including DORAs. While lemborexant's pharmacokinetics were studied in women within SUNRISE-1, the sex-stratified pharmacokinetic data from phase I studies suggest women have moderately higher exposure (area under the curve) than men at equivalent doses, likely reflecting differences in body composition and cytochrome P450 3A4 activity.

This means the 5 mg starting dose is especially appropriate as a first step for women, and the decision to move to 10 mg should be made conservatively.

Clinical Evidence: What SUNRISE-1 Found

The phase III SUNRISE-1 trial, published in JAMA Network Open in December 2019, was the key registration study for lemborexant. It enrolled 291 adults with insomnia disorder and randomized them to lemborexant 5 mg, lemborexant 10 mg, or placebo over 30 nights. The co-primary endpoints were subjective sleep onset latency and wake after sleep onset on nights 1 to 2 and at the end of month 1.

Both doses of lemborexant significantly outperformed placebo on sleep onset and maintenance. The 10 mg dose produced greater reductions in wake after sleep onset than the 5 mg dose. Critically, next-morning residual sleepiness assessed by driving simulation and the Digit Symbol Substitution Test showed no significant impairment versus placebo at the 5 mg dose, and only modest, transient effects at 10 mg on night 1.

The trial included a meaningful proportion of women, reflecting insomnia's known female-predominant epidemiology. Insomnia affects approximately 1.4 times more women than men across all age groups, with the risk rising sharply at menopause.

A second phase III trial, SUNRISE-2, assessed longer-term use (up to 12 months) and also supported the drug's efficacy and tolerability profile. SUNRISE-2 data contributed to the FDA's full approval and to Health Canada's 2021 decision.

Lemborexant Across Female Life Stages

Insomnia does not affect all women equally at every life stage. The orexin system interacts with estrogen and progesterone pathways in ways that have only recently begun to be studied systematically.

Reproductive years

Women of reproductive age with insomnia disorder have disrupted sleep architecture that often tracks with the menstrual cycle. Progesterone has mild sedative properties through its metabolite allopregnanolone, so sleep quality typically worsens in the follicular phase when progesterone is low, and may transiently improve in the luteal phase before crashing premenstrually. Lemborexant's mechanism, dampening orexin-driven wakefulness, is theoretically cycle-agnostic. No published clinical data specifically characterizes lemborexant's efficacy across menstrual cycle phases.

PCOS and sleep

Women with polycystic ovary syndrome (PCOS) have a significantly elevated risk of obstructive sleep apnea and insomnia. One analysis found that sleep disorders affect up to 40% of women with PCOS. Any sedative-hypnotic, including DORAs, should be used cautiously in women with PCOS who have untreated sleep apnea, because the sedation could blunt arousal responses during apnea events. Screen for sleep apnea before prescribing.

Perimenopause

The perimenopausal transition is the single highest-risk period for new-onset insomnia in a woman's life. Up to 61% of perimenopausal women report sleep disturbances, driven by hot flashes, night sweats, mood disruption, and direct hormonal effects on sleep architecture including suppressed slow-wave sleep and reduced REM continuity.

Lemborexant addresses the hyperarousal component of perimenopausal insomnia by quieting the orexin wake-drive. It does not address vasomotor symptoms directly. A clinically practical framework for perimenopausal women with insomnia: first determine whether the sleep disruption is primarily vasomotor-driven (hot flashes waking the patient) or primarily hyperarousal-driven (inability to fall asleep or stay asleep without hot flashes). Vasomotor-driven insomnia in perimenopausal women benefits most from addressing the vasomotor cause first, with menopausal hormone therapy (MHT) or non-hormonal vasomotor treatments such as fezolinetant. Hyperarousal-driven insomnia, or insomnia that persists after vasomotor symptoms are controlled, is where lemborexant has a more targeted role.

Perimenopausal women are also more likely to be on medications that inhibit CYP3A4 (for example, certain antifungals, some antidepressants), which can raise lemborexant plasma levels and increase sedation risk. The recommended dose is 5 mg in the presence of moderate CYP3A4 inhibitors, and lemborexant is contraindicated with strong CYP3A4 inhibitors.

Postmenopause

In postmenopausal women, estrogen loss reduces progesterone-driven sleep facilitation, and the orexin system becomes a relatively larger driver of the wake-sleep balance. The Menopause Society (formerly NAMS) 2023 position statement on menopause-associated sleep disturbance notes that pharmacological treatment of insomnia in menopausal women should account for the higher baseline prevalence of OSA in this group and the potential for medication interactions with MHT.

Postmenopausal women on CYP3A4-inducing agents should be aware that these can lower lemborexant levels and reduce efficacy. Hepatic function tends to decline modestly with age; the maximum recommended dose in hepatic impairment is 5 mg.

Pregnancy and Lactation Safety

Lemborexant should be avoided during pregnancy. This is a firm clinical position, not a soft caution.

Pregnancy

No adequate and well-controlled studies have been conducted in pregnant women. In animal reproductive toxicity studies, lemborexant produced embryofetal toxicity at exposures similar to human therapeutic doses. The FDA prescribing information advises that the potential benefit to the mother must be weighed against the potential risk to the fetus, and in practice, that balance rarely justifies use during pregnancy.

Insomnia during pregnancy is common, affecting up to 78% of pregnant women in the third trimester, and the reflex to treat it pharmacologically is understandable. Cognitive behavioral therapy for insomnia (CBT-I) remains the first-line recommended treatment during pregnancy by both ACOG and the American Academy of Sleep Medicine. CBT-I has demonstrated efficacy in pregnant populations without fetal risk.

If you are pregnant or planning pregnancy, discuss stopping lemborexant with your prescriber before conception. Women of childbearing potential should use effective contraception while taking lemborexant, given the embryofetal risk signal.

Lactation

No human data exist on lemborexant transfer into breast milk. Animal data indicate that lemborexant and its metabolites are present in milk. Because of the potential for central nervous system depression in a breastfed infant and the general absence of safety data, the prescribing information advises against use during breastfeeding.

The LactMed database and FDA label both reflect this absence-of-data position. If a postpartum woman with severe, treatment-resistant insomnia needs pharmacological management while breastfeeding, the risk-benefit conversation should include infant exposure risk and the availability of CBT-I as a safe alternative.

Contraception guidance

Women of reproductive potential taking lemborexant should use highly effective contraception. No specific contraceptive method is required by label, but the embryofetal toxicity signal means unintended pregnancy during treatment carries real fetal risk. Intrauterine devices, implants, or combination hormonal contraceptives are appropriate options. Note that lemborexant is metabolized by CYP3A4, and while enzyme-inducing contraceptives (rifampin-type interactions) could theoretically reduce lemborexant levels, standard combined oral contraceptives do not significantly induce CYP3A4 and are not expected to cause clinically meaningful interactions.

Who This Is Right For and Who Should Look at Other Options

Lemborexant is a reasonable choice when:

• You have chronic insomnia disorder with sleep-onset or sleep-maintenance difficulty, confirmed by clinical assessment.
• You have tried and found insufficient benefit from CBT-I, or you need pharmacological bridging while starting CBT-I.
• You are in the perimenopausal or postmenopausal stage and your insomnia has a significant hyperarousal component beyond just vasomotor symptom disruption.
• You need a sleep agent with a lower next-morning residual sedation profile than older benzodiazepines or z-drugs.
• You are at risk for dependence and prefer a Schedule IV agent with an orexin-specific mechanism that does not globally suppress CNS function.

Lemborexant is not appropriate when:

• You are pregnant or actively trying to conceive.
• You are breastfeeding.
• You have narcolepsy. DORAs are contraindicated in narcolepsy because the orexin system is already deficient.
• You have severe hepatic impairment (Child-Pugh C). This is a contraindication in the prescribing information.
• You are taking strong CYP3A4 inhibitors (for example, clarithromycin, itraconazole, some HIV protease inhibitors). Co-administration is contraindicated.
• You have untreated, moderate-to-severe obstructive sleep apnea.
• You live in the EU or UK and lack access to lemborexant through licensed channels. In these regions, suvorexant (Belsomra) is the available DORA.

Dosing Details Women Should Know

The recommended starting dose for all adults, including women, is 5 mg taken orally no more than once per night, immediately before going to bed, with at least 7 hours remaining before the planned awakening time. The dose may be increased to 10 mg based on efficacy and tolerability.

Sex-specific pharmacokinetic data indicate women have higher systemic exposure than men at the same dose, consistent with body-composition differences and typical CYP3A4 variability. While the FDA did not mandate a sex-specific starting dose the way it did for zolpidem, the clinical implication is that women should be especially cautious about uptitrating to 10 mg until they have assessed their individual response at 5 mg over at least a week.

The drug should be taken with or without food, but fatty meals delay the time to peak concentration (Tmax) and may slow sleep onset. Taking lemborexant on an empty stomach or with a light snack is preferable for fastest effect.

Do not take lemborexant unless you can dedicate a full night to sleep. Taking it and then waking within 4 to 5 hours significantly increases next-morning impairment risk.

Interactions Particularly Relevant to Women

Women taking lemborexant are more likely than men to be co-prescribed certain drug classes, and the interaction profile is worth knowing explicitly.

Antidepressants: SSRIs and SNRIs commonly used in women for depression, anxiety, premenstrual dysphoric disorder, and perimenopausal mood symptoms are generally weak CYP3A4 inhibitors or not CYP3A4 inhibitors at all. Fluoxetine is a moderate CYP2D6 inhibitor but does not meaningfully affect lemborexant's CYP3A4-mediated clearance. Fluvoxamine is a moderate CYP3A4 inhibitor and may raise lemborexant exposure; the label recommends capping dose at 5 mg with moderate CYP3A4 inhibitors.

Benzodiazepines and z-drugs: Combining lemborexant with other CNS depressants is not recommended. Additive sedation effects apply.

Menopausal hormone therapy: No direct pharmacokinetic interaction has been documented between MHT (estradiol, progesterone preparations) and lemborexant. Oral progesterone (micronized progesterone, Prometrium) has mild sedating properties of its own through allopregnanolone and could produce additive sedation at bedtime. Monitoring sleep quality and morning alertness after starting or adjusting MHT doses is reasonable.

Alcohol: Additive CNS depression. Avoid alcohol on any night lemborexant is taken.

Comparing Lemborexant to Other Sleep Options for Women

The DORA class is not the only pharmacological option for insomnia, and women need context to discuss choices with their prescriber.

| Drug | Class | FDA-approved for women | Pregnancy category | Key female-specific note | |---|---|---|---|---| | Lemborexant (Dayvigo) | DORA | Yes (adults) | Avoid, animal toxicity | Higher exposure in women; 5 mg preferred start | | Suvorexant (Belsomra) | DORA | Yes (adults) | Avoid | Available EU and UK; similar cautions | | Zolpidem (Ambien) | Z-drug (GABA-A) | Yes; 5 mg dose for women specifically | Avoid (neonatal withdrawal risk) | FDA mandated lower dose for women in 2013 | | Doxepine 3-6 mg (Silenor) | TCA (histamine) | Yes | Avoid | Sleep maintenance only; anticholinergic load matters in older women | | Low-dose trazodone | Off-label sedating antidepressant | Off-label use only | Caution | Widely used off-label; limited controlled trial data | | CBT-I | Behavioral | First-line all stages | Safe | Recommended first-line by AASM and ACOG throughout pregnancy and postpartum |

The Evidence Gap in Women

Women were historically underrepresented in sleep medication trials. SUNRISE-1 enrolled a majority female sample, which is more representative than older benzodiazepine-era trials, but sex-stratified efficacy and pharmacokinetic analyses were not the primary focus of published reports. The question of how insomnia phenotype, menstrual phase, hormonal contraceptive use, or menopausal status affects response to lemborexant specifically has not been addressed in any published trial to date.

This is an honest limitation. The guidance to start at 5 mg and the general pharmacokinetic caution about higher female exposure are extrapolated from broader PK data rather than from a prospectively designed female-focused clinical trial. Women deserve that trial. Until it exists, clinical management should lean conservative, with the lowest effective dose, attention to co-medications, and reassessment of ongoing need at each visit.

As stated in the 2023 Menopause Society Clinical Practice Statement on sleep: "Treatment decisions for menopause-associated insomnia should be individualized, with attention to the underlying etiology of sleep disturbance, comorbidities, and drug interactions."